Why the study?
Does coadministration of azithromycin affect the pharmacokinetics or pharmacodynamics (QTc interval) of terfenadine in healthy men?
Does coadministration of azithromycin affect the pharmacokinetics or pharmacodynamics (QTc interval) of terfenadine in healthy men?
Coadministration of azithromycin and terfenadine does not result in a clinically significant pharmacokinetic interaction or incremental QTc prolongation, suggesting macrolide-associated life-threatening arrhythmias are unlikely with this specific combination.
No QTc or pharmacokinetic interaction supports safe azithromycin-terfenadine coadministration; confirms azithromycin differs from other macrolides.
A double-blind placebo-controlled study was conducted in healthy men to determine the effect of coadministration of azithromycin on the pharmacodynamics and pharmacokinetics of terfenadine. Administration of 500 mg azithromycin for 1 day and 250 mg on 4 subsequent days did not affect the pharmacokinetics of the pharmacologically active terfenadine carboxylate metabolite when 60 mg terfenadine was given twice daily for 12 days, starting 7 days before azithromycin administration. Terfenadine alone resulted in a 0.010 msec increase in the rate-corrected QT interval (QTc), but the incremental effects of azithromycin and placebo on QTc in volunteers receiving terfenadine were not statistically different. It is concluded that the potentially life-threatening disorders that have been attributed to a pharmacokinetic interaction between macrolide antibiotics and terfenadine are unlikely to take place in patients treated simultaneously with azithromycin and terfenadine.
No takes yet. Share an insight, caveat, or question.
Harris et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: